Tofacitinib citrate | Tasocitinib citrate;CP-690550 citrate;CP 690,550;Tofacitinib (citrate) | 柠檬酸托法替尼 | JAK

首页 / / / JAK / Tofacitinib citrate

枸橼酸托法替尼 /Tofacitinib citrate 99%

货号：A118834 同义名： 柠檬酸托法替尼 / Tasocitinib citrate;CP-690550 citrate

Tofacitinib citrate是一种口服有效的JAK1/2/3抑制剂，其IC50值分别为1、20和112 nM。它还具有抗细菌、抗真菌和抗病毒特性。

Tofacitinib citrate 化学结构
CAS号：540737-29-9

Tofacitinib citrate 3D分子结构
CAS号：540737-29-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Tofacitinib citrate 纯度/质量文件产品仅供科研

货号：A118834 标准纯度： 99% 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell,2024. Ambeed. [ A125712 ]; • Cancer Discov., 2024. Ambeed. [ A285925 ]; • JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]; • JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]; • EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]; 更多 >

JAK 亚型比较

产品名称	JAK1 ↓ ↑	JAK2 ↓ ↑	JAK3 ↓ ↑	Tyk2 ↓ ↑	其他靶点	纯度
Decernotinib	+++ JAK1, IC50: 11 nM JAK1, Ki: 11 nM	+++ JAK2, Ki: 13 nM	++++ JAK3, Ki: 2.5 nM	+++ TYK2, Ki: 13 nM		99%+
ZM39923 HCl	+ JAK1, pIC50: 4.4		+ JAK3, pIC50: 7.1		EGFR	97%
Cerdulatinib	+++ JAK1, IC50: 12 nM	+++ JAK2, IC50: 6 nM	+++ JAK3, IC50: 8 nM	++++ TYK2, IC50: 0.5 nM		99%+
Momelotinib	+++ JAK1, IC50: 11 nM	++ JAK2, IC50: 18 nM	+ JAK3, IC50: 155 nM			99%+
XL019	+ JAK1, IC50: 134.3 nM	++++ JAK2, IC50: 2.2 nM	+ JAK3, IC50: 214.2 nM		FLT3	99%+
Ruxolitinib	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM				98%
Tofacitinib	+ JAK1, IC50: 112 nM	++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			98%
Ruxolitinib (S enantiomer)	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM		++ TYK2, IC50: 19 nM		98%
Filgotinib	+++ JAK1, IC50: 10 nM	++ JAK2, IC50: 28 nM	+ JAK3, IC50: 810 nM	+ TYK2, IC50: 116 nM		99%
Baricitinib	+++ JAK1, IC50: 5.9 nM	+++ JAK2, IC50: 5.7 nM		++ TYK2, IC50: 53 nM		99%
Gandotinib	++ JAK1, IC50: 19.8 nM	++++ JAK2 (V617F), Ki: 0.245 nM JAK2, IC50: 0.288 nM	++ JAK3, IC50: 48.0 nM	++ TYK2, IC50: 44 nM	FLT3	99%+
Oclacitinib maleate	+++ JAK1, IC50: 10nM	++ JAK2, IC50: 18nM	+ JAK3, IC50: 99nM	+ TYK2, IC50: 84nM		98+%
NVP-BSK805 2HCl	++ JAK1, IC50: 31.63 nM	++++ JAK2, IC50: ~0.5 nM	++ JAK3, IC50: 18.68 nM	+++ TYK2, IC50: 10.76 nM		99+%
Peficitinib		✔				98%
Go6976		✔			FLT3	99%+
AZD-1480		++++ JAK2, IC50: 0.26 nM				99%+
Fedratinib		+++ JAK2 (V617F), IC50: 3 nM JAK2, IC50: 3 nM			RET,FLT3	99%+
WP1066		+ JAK2, IC50: 2.3 μM				98%
Curcumol		✔				98%
AZ960		++++ JAK2, Ki: 0.45 nM JAK2, IC50: <3 nM				97%
GLPG0634 analog		✔				99%+
CEP-33779		++++ JAK2, IC50: 1.8 nM				99%+
FLLL32		+ JAK2, IC50: <5 μM				99%+
WHI-P154			+ JAK3, IC50: 1.8 μM		EGFR,VEGFR,Src	98%
BMS-911543		++++ JAK2, IC50: 1.1 nM	+ JAK3, IC50: 75 nM	++ TYK2, IC50: 66 nM		98%
TG101209		+++ JAK2, IC50: 6 nM	+ JAK3, IC50: 169 nM		RET,FLT3	99%+
AT9283		++++ JAK2, IC50: 1.2 nM	++++ JAK3, IC50: 1.1 nM			99%+
Pacritinib		++ JAK2 (V617F), IC50: 19 nM JAK2, IC50: 23 nM	+ JAK3, IC50: 520 nM	++ TYK2, IC50: 50 nM	FLT3	97%
Tofacitinib citrate		++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			99%
FM-381			++++ JAK3, IC50: 127 pM			98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Tofacitinib citrate 生物活性

靶点

JAK3

JAK3, IC50:1 nM
JAK2

JAK2, IC50:20 nM

描述

Tofacitinib Citrate is the citrate form of Tofacitinib. Tofacitinib is an ATP-competed inhibitor of JAK with IC50 values of 3.2±1.4 nM, 4.1±0.4 nM, 1.6±0.2 nM, 34.0±6.0 nM for JAK1, JAK2, JAK3 and TYK2 in in vitro enzyme assays. It competes with ATP for binding to the active site of the kinase domain of JAKs with Ki values of 0.68 ± 0.12 nM (JAK1), 0.99 ± 0.04 nM (JAK2), 0.24 ± 0.02 nM (JAK3) and 4.39 ± 0.27 nM (TYK2). Tofacitinib potently inhibits multiple cytokine activated JAK/STAT signaling pathways in normal human, mouse or rat whole blood with IC50s below 200 nM. Selectivity assessed in mouse and rat whole blood shows that tofacitinib appears to be more potently to JAK1 and JAK3. In cell assays, tofacitinib inhibits human total myeloid and CFU-G colony formation with IC50s of 0.87 and 0.93 μM. In AIA rats, tofacitinib treatment can decrease paw volume and disease-elevated neutrophil count to normal range compared to vehicle treated control rats. Tofacitinib treatment also dose-dependently decreased both IL-17 and IL-6 of the AIA-induced increase compared to control levels with an approximately 80% inhibition. It significantly inhibits the AIA-induced increase in maturing myeloid cells by approximately 50% at the 10 mg/kg dose^[3]. Tofacitinib has been approved by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colitis^[1].

Tofacitinib citrate 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
Ba/F3 cells		Function assay	60 mins	Inhibition of TEL-fused JAK1 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay, IC50=26 nM.	22087750
Ba/F3 cells		Function assay	60 mins	Inhibition of TEL-fused JAK3 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay, IC50=54 nM.	22087750
human CD4+ T cells	5 to 500 nM	Function assay	1 h	Inhibition of IL2-induced Stat5 phosphorylation in human CD4+ T cells at 5 to 500 nM after 1 hr by Western blot	19053756
human DND/L12 cells		Function assay	30 mins	Inhibition of JAK3 in human DND/L12 cells after 30 mins by luciferase assay in presence of human serum albumin.	14593182

Tofacitinib citrate 动物研究

Dose	Rat: 5 mg/kg - 50 mg/kg^[3] (i.v.), 10 mg/kg - 100 mg/kg^[4] (p.o.) Mice: 1 mg/kg - 100 mg/kg^[5] (p.o.)
Administration	i.v., p.o.

Tofacitinib citrate 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01023100	Arthritis, Rheumatoid	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Pfizer Investigational Site Woburn, Massachusetts, United States, 01801 收起 <<
NCT01185184	Healthy	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT01246583	Psoriasis	Phase 2	Completed	-	United States, Alabama ... 展开 >> Pfizer Investigational Site Mobile, Alabama, United States, 36606 United States, California Pfizer Investigational Site Los Angeles, California, United States, 90045 United States, Florida Pfizer Investigational Site Orange Park, Florida, United States, 32073 United States, Nebraska Pfizer Investigational Site Omaha, Nebraska, United States, 68144 United States, New Mexico Pfizer Investigational Site Albuquerque, New Mexico, United States, 87106 United States, South Dakota Pfizer Investigational Site Rapid City, South Dakota, United States, 57702 United States, Texas Pfizer Investigational Site Dallas, Texas, United States, 75231 Canada, Ontario Pfizer Investigational Site Waterloo, Ontario, Canada, N2J 1C4 Canada, Quebec Pfizer Investigational Site Montreal, Quebec, Canada, H2K 4L5 Pfizer Investigational Site Montreal, Quebec, Canada, H3Z 2S6 Canada Pfizer Investigational Site Quebec, Canada, G1V 4X7 收起 <<

Tofacitinib citrate 参考文献

[1]Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010 Aug 11;7:41. doi: 10.1186/1476-9255-7-41. PMID: 20701804; PMCID: PMC2928212.

[2]Lloyd-Lavery A. Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis. Br J Dermatol. 2018;179(4):815-816.

[3]Lloyd-Lavery A. Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis. Br J Dermatol. 2018 Oct;179(4):815-816. doi: 10.1111/bjd.17016. PMID: 30318813.

Tofacitinib citrate 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.98mL

0.40mL

0.20mL

9.91mL

1.98mL

0.99mL

19.82mL

3.96mL

1.98mL

Tofacitinib citrate 技术信息

CAS号	540737-29-9
分子式	C₂₂H₂₈N₆O₈
分子量	504.493

别名	柠檬酸托法替尼 ;Tasocitinib citrate;CP-690550 citrate;CP 690,550;Tofacitinib (citrate)
运输	蓝冰

存储条件

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 25 mg/mL(49.55 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 3 mg/mL(5.95 mM)，配合低频超声助溶

动物实验配方

IP 2% DMSO+water 2 mg/mL clear

PO 0.5% CMC-Na 80 mg/mL suspension

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01023100	Arthritis, Rheumatoid	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Pfizer Investigational Site Woburn, Massachusetts, United States, 01801 收起 <<
NCT01185184	Healthy	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT01246583	Psoriasis	Phase 2	Completed	-	United States, Alabama ... 展开 >> Pfizer Investigational Site Mobile, Alabama, United States, 36606 United States, California Pfizer Investigational Site Los Angeles, California, United States, 90045 United States, Florida Pfizer Investigational Site Orange Park, Florida, United States, 32073 United States, Nebraska Pfizer Investigational Site Omaha, Nebraska, United States, 68144 United States, New Mexico Pfizer Investigational Site Albuquerque, New Mexico, United States, 87106 United States, South Dakota Pfizer Investigational Site Rapid City, South Dakota, United States, 57702 United States, Texas Pfizer Investigational Site Dallas, Texas, United States, 75231 Canada, Ontario Pfizer Investigational Site Waterloo, Ontario, Canada, N2J 1C4 Canada, Quebec Pfizer Investigational Site Montreal, Quebec, Canada, H2K 4L5 Pfizer Investigational Site Montreal, Quebec, Canada, H3Z 2S6 Canada Pfizer Investigational Site Quebec, Canada, G1V 4X7 收起 <<
NCT01101919	Healthy	Phase 1	Completed	-	China ... 展开 >> Pfizer Investigational Site Beijing, China, 100032 收起 <<
NCT01470599	Crohn's Disease	Phase 2	Completed	-	-
NCT01470599	-		Completed	-	-
NCT01710020	End-Stage Renal Disease ... 展开 >> Hemodialysis 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Pfizer Investigational Site Orlando, Florida, United States, 32806 United States, Minnesota Pfizer Investigational Site Minneapolis, Minnesota, United States, 55404 收起 <<
NCT01470612	Ulcerative Colitis	Phase 3	Active, not recruiting	July 27, 2020	-
NCT01710033	Kidney Transplant	Phase 1	Completed	-	United States, Alabama ... 展开 >> Pfizer Investigational Site Birmingham, Alabama, United States, 35249-6860 Pfizer Investigational Site Birmingham, Alabama, United States, 35249 Pfizer Investigational Site Birmingham, Alabama, United States, 35294-6862 United States, California Pfizer Investigational Site Los Angeles, California, United States, 90057 United States, Indiana Pfizer Investigational Site Indianapolis, Indiana, United States, 46202 United States, Minnesota Pfizer Investigational Site Minneapolis, Minnesota, United States, 55404 United States, Missouri Pfizer Investigational Site St Louis, Missouri, United States, 63110-1093 Pfizer Investigational Site St. Louis, Missouri, United States, 63110-1092 United States, New Jersey Pfizer Investigational Site Livingston, New Jersey, United States, 07039 United States, Wisconsin Pfizer Investigational Site Madison, Wisconsin, United States, 53792 收起 <<
NCT01710020	-		Completed	-	-
NCT01710033	-		Completed	-	-
NCT01277991	Arthritis, Rheumatoid	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT01740362	Renal Impairment	Phase 1	Completed	-	United States, Florida ... 展开 >> Pfizer Investigational Site Orlando, Florida, United States, 32806 United States, Louisiana Pfizer Investigational Site New Orleans, Louisiana, United States, 70118 Pfizer Investigational Site New Orleans, Louisiana, United States, 70119 United States, Minnesota Pfizer Investigational Site Minneapolis, Minnesota, United States, 55404 收起 <<
NCT01740362	-		Completed	-	-
NCT01241591	Psoriasis	Phase 3	Completed	-	-
NCT01241591	-		Completed	-	-
NCT01504113	-		Unknown	June 2015	Taiwan ... 展开 >> National Taiwan University Dermatology department Recruiting Taipei, Taiwan, 100 Contact: Tsen-Fang Tsai, M.D. 886-2-23562141 tftsai@yahoo.com Contact: Hsien-Yi Chiu, M.D. 886-2-23123456 ext 29252192 extra.owl@msa.hinet.net Principal Investigator: Hsien-yi Chiu, M.D. 收起 <<
NCT01458574	Ulcerative Colitis	Phase 3	Completed	-	-
NCT01186744	Psoriasis	Phase 3	Completed	-	-
NCT01519089	Psoriasis	Phase 3	Completed	-	Japan ... 展开 >> JR Sapporo hospital Sapporo, Hokkaido, Japan, 060-0033 Kobe University Hospital Chuo-ku, Kobe, Hyogo, Japan, 650-0017 Kanazawa Medical University Hospital Kahoku-gun, Ishikawa, Japan, 920-0293 National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan, 252-0392 University of Miyazaki Hospital Miyazaki-shi, Miyazaki, Japan, 889-1692 Jichi Medical University Hospital Shimotsuke, Tochigi, Japan, 324-0498 Tokyo Teishin Hospital Chiyoda-ku, Tokyo, Japan, 102-8798 Tokyo medical university Hachioji medical center Hachioji, Tokyo, Japan, 193-0998 Kanto Medical Center NTT East Corporation Shinagawa-ku, Tokyo, Japan, 141-8625 Tokyo Medical University Hospital Shinjyuku-ku, Tokyo, Japan, 160-0023 Tonami General Hospital Tonami, Toyama, Japan, 939-1395 Yamanashi Prefectural Central Hospital Kofu, Yamanashi, Japan, 400-8506 Fukuoka University Hospital Fukuoka, Japan, 814-0180 Fukushima Medical University Hospital Fukushima, Japan, 960-1295 Nissay Hospital Osaka, Japan, 550-0012 Jikei University Hospital Tokyo, Japan, 105-8471 收起 <<
NCT00658359	-		Completed	-	-
NCT00658359	Kidney Transplantation	Phase 2	Completed	-	-
NCT01458574	-		Completed	-	-
NCT01276639	-		Completed	-	-
NCT01186744	-		Completed	-	-
NCT01815424	Psoriasis	Phase 3	Completed	-	China, Beijing ... 展开 >> Dept. Of dermatology &STD, Beijing Friendship Hospital, Capital Medical University Xicheng District, Beijing, China, 100050 China, Guangdong Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China, 510120 China, Hubei Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China, 430022 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China, 430030 China, Jiangsu Hospital of Skin Diseases, Chinese Academy of Medical Sciences Nanjing, Jiangsu, China, 210042 China, Liaoning Department of Dermatology, The Second Affiliated Hospital of Dalian Medical University Dalian, Liaoning, China, 116027 China, Shanghai Huashan Hospital, Fudan University/Dermatology Department Shanghai, Shanghai, China, 200040 Shanghai Changhai Hospital, Dermatology Department Shanghai, Shanghai, China, 200433 China, Shanxi Dermatology Department, The First Affiliated Hospital, The Fourth Military Medical University Xi'an, Shanxi, China, 710032 China, Sichuan Sichuan Provincial People's Hospital Chengdu, Sichuan, China, 610031 West China Hospital of Sichuan University Chengdu, Sichuan, China, 610041 China, Zhejiang The First Affiliated Hospital of College of Medicine, Zhejiang University/Dermatology and STD Dept Hangzhou, Zhejiang, China, 310003 The Second Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou, Zhejiang, China, 310009 China Peking University First Hospital / The Department of Dermatology Beijing, China, 100034 Peking University People's Hospital/Dermatology Department Beijing, China, 100044 Beijing Hospital of the Ministry of Health/Department of Dermatology Beijing, China, 100730 Peking Union Medical College Hospital/Department of Dermatology Beijing, China, 100730 Tianjin Medical University General Hospital, Dermatological Department Tianjin, China, 300052 Korea, Republic of Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Department of Dermatology,Severance Hospital, Yonsei University Health System Seoul, Korea, Republic of, 120-452 Samsung Medical Center Seoul, Korea, Republic of, 135-710 Taiwan National Cheng-Kung University Hospital Tainan, Taiwan, 704 National Taiwan University Hospital Taipei, Taiwan, 100 Chang Gung Medical Foundation-Linkou Branch Taoyuan, Taiwan, 333 收起 <<
NCT01393626	Crohn's Disease	Phase 2	Completed	-	-
NCT01393626	-		Completed	-	-
NCT01309737	Psoriasis	Phase 3	Completed	-	-
NCT01519089	-		Completed	-	-
NCT00263328	Kidney Transplantation	Phase 2	Completed	-	United States, California ... 展开 >> Multi Organ Transplant Center Los Angeles, California, United States, 90057 St. Vincent Medical Center Los Angeles, California, United States, 90057 Transplant Research Institute Los Angeles, California, United States, 90057 Stanford School of Medicine Palo Alto, California, United States, 94304 Balboa Institute of Transplantation San Diego, California, United States, 92123 California Institute of Renal Research San Diego, California, United States, 92123 Sharp Memorial Hospital San Diego, California, United States, 92123 California Pacific Medical Center San Francisco, California, United States, 94115 University of California, San Francisco, Kidney Transplant Unit San Francisco, California, United States, 94143 Stanford University Medical Center Stanford, California, United States, 94305 United States, Colorado University of Colorado Health Sciences Center Renal Clinical Trials Office Aurora, Colorado, United States, 80045 University of Colorado Health Sciences Center Aurora, Colorado, United States, 80045 United States, Illinois Northwestern Memorial Hospital Chicago, Illinois, United States, 60611 Northwestern University-Feinberg School of Medicine, Division of Organ Transplantation Chicago, Illinois, United States, 60611 United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States, 63110 United States, New York Jack J Dreyfus Clinic New York, New York, United States, 10021 Recanati/Miller Transplantation Institute New York, New York, United States, 10029 New York Presbyterian Hospital / Weill Cornell Medical Center New York, New York, United States, 10065 United States, Oregon Legacy Good Samaritan Hospital Portland, Oregon, United States, 97210 Legacy Transplant Services Portland, Oregon, United States, 97210 Northwest Renal Clinic Portland, Oregon, United States, 97210 United States, Texas Dallas Transplant Institute Dallas, Texas, United States, 75204 Annette C & Harold C Simmons Transplant Institute Dallas, Texas, United States, 75246 Baylor University Medical Center Dallas, Texas, United States, 75246 Baylor All Saints Medical Center Fort Worth, Texas, United States, 76104 United States, Wisconsin Froedtert Memorial Lutheran Hospital Milwaukee, Wisconsin, United States, 53226 Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT01276639	Psoriasis	Phase 3	Completed	-	-
NCT01309737	-		Completed	-	-
NCT01163253	Psoriasis	Phase 3	Terminated	-	-
NCT00263328	-		Completed	-	-
NCT00106639	Kidney Transplantation	Phase 2	Completed	-	United States, California ... 展开 >> Pfizer Investigational Site Los Angeles, California, United States, 90057 Pfizer Investigational Site Los Angeles, California, United States, 92356 Pfizer Investigational Site Palo Alto, California, United States, 94304 Pfizer Investigational Site San Diego, California, United States, 92123 Pfizer Investigational Site San Francisco, California, United States, 94115 Pfizer Investigational Site San Francisco, California, United States, 94143-0780 Pfizer Investigational Site Stanford, California, United States, 94305 United States, Colorado Pfizer Investigational Site Denver, Colorado, United States, 80262 United States, Illinois Pfizer Investigational Site Chicago, Illinois, United States, 60611 United States, Louisiana Pfizer Investigational Site New Orleans, Louisiana, United States, 70112 United States, Missouri Pfizer Investigational Site St. Louis, Missouri, United States, 63110-1092 Pfizer Investigational Site St. Louis, Missouri, United States, 63110 United States, New Jersey Pfizer Investigational Site Livingston, New Jersey, United States, 07039 United States, New York Pfizer Investigational Site New York, New York, United States, 10021 Pfizer Investigational Site New York, New York, United States, 10029 United States, Oregon Pfizer Investigational Site Portland, Oregon, United States, 97210 United States, Texas Pfizer Investigational Site Dallas, Texas, United States, 75204 Pfizer Investigational Site Dallas, Texas, United States, 75246 United States, Virginia Pfizer Investigational Site Richmond, Virginia, United States, 23298 United States, Wisconsin Pfizer Investigational Site Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT01163253	-		Terminated	-	-
NCT01736696	Psoriasis Imm... 展开 >>unomodulation 收起 <<	Phase 1	Completed	-	United States, Arkansas ... 展开 >> Pfizer Investigational Site Little Rock, Arkansas, United States, 72202 收起 <<
NCT00106639	-		Completed	-	-
NCT00661661	Rheumatoid Arthritis	Phase 3	Completed	-	-
NCT01484561	-		Completed	-	-
NCT01393899	Crohn's Disease	Phase 2	Completed	-	-
NCT01736696	-		Completed	-	-
NCT03440892	-		Recruiting	January 2020	Sweden ... 展开 >> Dept of Rheumatology and Inflammation research Recruiting Gothenburg, Sweden Contact: Sofia T Silfverswärd sofia.silfversward@rheuma.gu.se 收起 <<
NCT00661661	-		Completed	-	-
NCT01484561	Arthritis, Rheumatoid	Phase 1	Completed	-	United States, Florida ... 展开 >> Pfizer Investigational Site South Miami, Florida, United States, 33143 United States, New York Pfizer Investigational Site Albany, New York, United States, 12206 United States, Pennsylvania Pfizer Investigational Site Duncansville, Pennsylvania, United States, 16635 United States, Texas Pfizer Investigational Site Dallas, Texas, United States, 75231 United States, Washington Pfizer Investigational Site Tacoma, Washington, United States, 98405 Czech Republic Pfizer Investigational Site Praha 4, Czech Republic, 140 59 Germany Pfizer Investigational Site Berlin, Germany, 13125 Pfizer Investigational Site Erlangen, Germany, 91054 Pfizer Investigational Site Wuerzburg, Germany, 97080 Korea, Republic of Pfizer Investigational Site Seoul, Korea, Republic of, 120-752 Mexico Pfizer Investigational Site Merida, Yucatan, Mexico, 97000 Poland Pfizer Investigational Site Bialystok, Poland, 15-354 Pfizer Investigational Site Bydgoszcz, Poland, 85-168 Pfizer Investigational Site Warszawa, Poland, 01-192 Pfizer Investigational Site Warszawa, Poland, 02-256 Pfizer Investigational Site Wroclaw, Poland, 50-088 Russian Federation Pfizer Investigational Site Moscow, Russian Federation, 115522 Pfizer Investigational Site Petrozavodsk, Russian Federation, 185019 Pfizer Investigational Site Saint Petersburg, Russian Federation, 197341 Pfizer Investigational Site St. Petersburg, Russian Federation, 194291 Spain Pfizer Investigational Site Barakaldo, Vizcaya, Spain, 48903 Pfizer Investigational Site Bilbao, Vizcaya, Spain, 48013 Pfizer Investigational Site La Coruna, Spain, 15006 Pfizer Investigational Site Sevilla, Spain, 41009 收起 <<
NCT01710046	Plaque Psoriasis	Phase 2	Completed	-	United States, California ... 展开 >> Dermatology Research Associates Los Angeles, California, United States, 90045 United States, Florida Olympian Clinical Research Tampa, Florida, United States, 33609 United States, Texas Menter Dermatology Research Institute Dallas, Texas, United States, 75246 Center for Clinical Studies Houston, Texas, United States, 77004 Center for Clinical Studies Houston, Texas, United States, 77030 收起 <<
NCT01710046	-		Completed	-	-
NCT02193815	Psoriasis Vulgaris	Phase 1	Completed	-	Germany ... 展开 >> Bioskin GmbH Hamburg, Germany, 20095 收起 <<
NCT02193815	-		Completed	-	-
NCT01741493	Rheumatoid Arthritis	Phase 1	Completed	-	United States, Florida ... 展开 >> Site Reference ID/Investigator# 95817 Miami, Florida, United States, 33136 United States, Ohio Site Reference ID/Investigator# 95816 Cincinnati, Ohio, United States, 45255 United States, Pennsylvania Site Reference ID/Investigator# 95815 Duncansville, Pennsylvania, United States, 16635 United States, Texas Site Reference ID/Investigator# 92153 Austin, Texas, United States, 78744 United States, Utah Site Reference ID/Investigator# 97177 Orem, Utah, United States, 84058 收起 <<
NCT01393899	-		Completed	-	-
NCT01745055	-		Completed	-	-
NCT01513902	Juvenile Idiopathic Arthritis	Phase 1	Completed	-	United States, Minnesota ... 展开 >> Explorer Clinic, University of Minnesota Children's Hospital Minneapolis, Minnesota, United States, 55454 Clinical and Translational Science Institute Masonic Clinical Research Unit (Administration Only) Minneapolis, Minnesota, United States, 55455 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Oregon Randall Children's Hospital at Legacy Emanuel Portland, Oregon, United States, 97227 Germany PRI - Pediatric Rheumatology Research Institute GmbH Bad Bramstedt, Germany, 24576 Hamburger Zentrum fuer Kinder-und Jugendrheumatologie SchoenKlinik Hamburg Eilbek Hamburg, Germany, 22081 Asklepios Klinik Sankt Augustin Gmbh St. Augustin, Germany, 53757 Poland Wojewodzki Specjalistyczny Szpital Dzieciecy im. Sw. Ludwika w Krakowie Krakow, Poland, 31-503 Klinika Kardiologii i Reumatologii Dzieciecej Lodz, Poland, 91-738 Slovakia Narodny ustav reumatickych chorob Piestany, Slovakia, 921 12 收起 <<
NCT03281304	Ulcerative Colitis	Phase 3	Recruiting	November 22, 2022	-
NCT00413699	Arthritis, Rheumatoid	Phase 3	Completed	-	-
NCT01458951	Ulcerative Colitis	Phase 3	Completed	-	-
NCT00413699	-		Completed	-	-
NCT01458951	-		Completed	-	-
NCT03016884	Herpes Zoster	Phase 4	Recruiting	May 2019	Israel ... 展开 >> Ha'Emek Medical center, Unit of Rheumatology Recruiting Afula, Israel Contact: Amir Bieber, MD 972-52-6054854 amir.bieber@gmail.com Carmel Medical Center Recruiting Haifa, Israel Contact: Devi Zissman, MD 972-4-8250486 Tel Aviv Medical Center, Unit pf Rheumatology Recruiting Tel Aviv, Israel Contact: Ori Elkayam, MD 972-3-6973248 rheumatology@tlvmc.gov.il 收起 <<
NCT01745055	Rheumatoid Arthritis	Phase 1	Completed	-	United States, Florida ... 展开 >> Pfizer Investigational Site Daytona Beach, Florida, United States, 32114 Pfizer Investigational Site Fort Lauderdale, Florida, United States, 33301 Pfizer Investigational Site Miramar, Florida, United States, 33025 United States, Texas Pfizer Investigational Site Dallas, Texas, United States, 75247 收起 <<
NCT02996500	Rheumatoid Arthritis	Phase 2	Completed	-	-
NCT01465763	Ulcerative Colitis	Phase 3	Completed	-	-
NCT01465763	-		Completed	-	-
NCT03073109	-		Recruiting	February 22, 2019	Colombia ... 展开 >> Artmedica Recruiting Medellin, Antioquia, Colombia Hospital Pablo Tobon Uribe Not yet recruiting Medellin, Antioquia, Colombia Fundacion Instituto de Reumatologia Fernando Chalem Recruiting Bogota, Cundinamarca, Colombia IDEARG Recruiting Bogota, Cundinamarca, Colombia Clinica de Occidente Recruiting Cali, Valle, Colombia Centro Integral de Reumatología del Caribe Circaribe S.A Recruiting Barranquilla, Colombia Clinicos IPS Recruiting Bogota, Colombia, 111211 Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM Recruiting Bogotá, Colombia SERVIMED Recruiting Bucaramanga, Colombia Fundacion Valle del Lili Recruiting Cali, Colombia REUMALAB Recruiting Medellin, Colombia Peru Clinica Delgado Not yet recruiting Miraflores, Lima, Peru Clínica San Judas Tadeo Recruiting Lima, SAN Miguel, Peru, 15086 Centro Medico CEEN Recruiting Arequipa, Peru Clinica Jockey Salud Recruiting Lima, Peru 收起 <<
NCT03103412	Active Mild Ulcerative Colitis... 展开 >>, Active Moderate Ulcerative Colitis, Healthy Subjects 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> Anaheim Clinical Trials, LLC Anaheim, California, United States, 92801 收起 <<
NCT01143805	Healthy	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT01513902	-		Completed	-	-
NCT02984020	-		Recruiting	January 2, 2020	Korea, Republic of ... 展开 >> Chonbuk National University Hospital, Department of Rheumatology Recruiting Chonju, Chonbuk, Korea, Republic of, 561-712 Dankook University Hospotal Recruiting Cheonan, Chung NAM, Korea, Republic of, 31116 Konkuk University Chungju Hospital Recruiting Chungju-si, Chungcheongbuk-do, Korea, Republic of, 27376 Soonchunhyang University Cheonan Hospital, Department of Rheumatology Recruiting Chunan-si, Chungcheongnam-do, Korea, Republic of, 330-721 Keimyung University Dongsan Medical Center Recruiting Jung-Gu, Daegu, Korea, Republic of, 700-712 Kongyang University Hospital / Rheumatology Recruiting Seo-gu, Daejon, Korea, Republic of, 35365 Kyung Hee University Hospital at Gangdong / Rheumatology Recruiting Seoul, Gangdong-gu, Korea, Republic of, 05278 VHS Medical Center / Rheumatologist Recruiting Seoul, Gangdong-gu, Korea, Republic of, 05367 Chosun University Hospital, Rheumatism Department Recruiting Dong Gu, Gwang JU, Korea, Republic of, 61453 Division of Rheumatology Recruiting Seongnam-si, Gyeongg-do, Korea, Republic of CHA Bundang Medical Center Recruiting Seongnam-si, Gyeonggi-do, Korea, Republic of, 13496 Pusan National University Yangsan Hospital Recruiting Yangsan-si, Gyeongsangnam-do, Korea, Republic of, 50612 Yangsan Hospital-Pusan National University Recruiting Yangsan-si, Gyeongsangnam-do, Korea, Republic of, 50612 Wonkwang University Hospital / Division of Rheumatology Recruiting Iksan, Jeonlabuk-do, Korea, Republic of, 570711 Ajou University Hospital, Department of Rheumatology Recruiting Suwon-si, Kyeongki-do, Korea, Republic of, 442-712 Korea University Ansan Hospital Recruiting Ansan, Gyeonggi-do, Korea, Republic of Inje University Busan Paik hospital Recruiting Busan, Korea, Republic of, 47392 Kosin University Gospel Hospital Recruiting Busan, Korea, Republic of, 607-702 Inje University Haeundae Paik Hospital Recruiting Busan, Korea, Republic of, 612-896 Chungbuk National University Hospital Recruiting Chungcheongbuk-do, Korea, Republic of, 28644 Daegu Catholic University Medical Center, Department of Rheumatology Recruiting Daegu, Korea, Republic of, 705-718 Eulji University Hospital, Internal Medicine, Rheumatology Recruiting Daejeon, Korea, Republic of, 302-799 Inje University IlsanPaik Hospital Recruiting Goyang-si, Gyeonggi-do, Korea, Republic of Dongguk University Ilsan Medical Center Recruiting Gyeonggi-do, Korea, Republic of Gachon University Gil Hospital Recruiting Incheon, Korea, Republic of, 405-760 Division of Rheumatology Recruiting Incheon, Korea, Republic of Jeju National University Hospital Recruiting Jeju Special Self-Goverming Province, Korea, Republic of Division of Rheumatology Recruiting Metropolitan City, Daejeon, Korea, Republic of Pusan National University Hospital Recruiting Pusan, Korea, Republic of, 602-739 Dong-A University Hospital Recruiting Pusan, Korea, Republic of Hanyang Rheuma Uhm Wan-Sik Clinic Terminated Seoul, Korea, Republic of, 04782 Division of Rheumatology, SMG-SNU Boramae Medical Center Recruiting Seoul, Korea, Republic of, 07061 Seoul National University Hospital, Department of Internal Medicine Recruiting Seoul, Korea, Republic of, 110-744 Seoul National University Hospital, Rheumatology, Internal Medicine Recruiting Seoul, Korea, Republic of, 110-744 Kyung Hee University Hospital Recruiting Seoul, Korea, Republic of, 130-872 Hanyang University Hospital, Department of Rheumatology Recruiting Seoul, Korea, Republic of, 133-792 Kyunghee University East-West Neo Medical Center, 149 Sangil-dong, Gangdong-gu Recruiting Seoul, Korea, Republic of, 134-890 Samsung Medical Center, Division of Rheumatology, Department of Medicine Recruiting Seoul, Korea, Republic of, 135-710 The Catholic University of Korea, Kangnam St. Mary's Hospital/ Rheumatology, Internal Medicine Recruiting Seoul, Korea, Republic of, 137-701 The Catholic University of Korea, Seoul St. Mary's Hospital/ Rheumatology, Internal Medicine Recruiting Seoul, Korea, Republic of, 137-701 Eulji Medical Center Active, not recruiting Seoul, Korea, Republic of, 139-711 Soonchunhyang University Hospital Seoul/Department of Rheumatology Recruiting Seoul, Korea, Republic of, 140-887 Konkuk University Medical Center Recruiting Seoul, Korea, Republic of, 143-729 Division of Rheumatology Recruiting Seoul, Korea, Republic of Ewha Womans University Mokdong Hospital Recruiting Seoul, Korea, Republic of Hallym University Kangnam Sacred Heart Hospital Active, not recruiting Seoul, Korea, Republic of Kyung Hee University Medical Center Recruiting Seoul, Korea, Republic of 收起 <<
NCT03643211	-		Recruiting	February 25, 2022	Japan ... 展开 >> Pfizer Local Country Office Recruiting Tokyo, Japan 收起 <<
NCT02157012	Rheumatoid Arthritis	Phase 4	Recruiting	March 2019	Japan ... 展开 >> Yukio Nakamura Recruiting Matsumoto, Nagano, Japan, 3908621 Contact: Yukio Nakamura, MD, PhD yxn14@aol.jp 收起 <<
NCT01375127	-		Completed	-	-
NCT03755466	Rheumatoid Arthritis	Phase 2	Recruiting	November 20, 2023	Japan ... 展开 >> Yukio Nakamura Recruiting Matsumoto, Nagano, Japan, 3908621 Contact: Yukio Nakamura, MD, PhD +81-263-37-2659 yxn14@aol.jp Principal Investigator: Yukio Nakamura, MD, PhD 收起 <<
NCT03112148	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer New Haven Clinical Research Unit New Haven, Connecticut, United States, 06511 收起 <<
NCT01877668	Psoriatic Arthritis	Phase 3	Completed	-	-
NCT03663400	-		Not yet recruiting	October 2019	United States, New York ... 展开 >> New York University School of Medicine Not yet recruiting New York, New York, United States, 10016 Contact: Gregory Pappas 212-263-3095 gregory.pappas@nyumc.org Principal Investigator: David Hudesman, MD 收起 <<
NCT01375127	-		Completed	-	-
NCT01831466	Psoriasis Vulgaris ... 展开 >> Psoriasis 收起 <<	Phase 2	Completed	-	-
NCT01877668	-		Completed	-	-
NCT03591770	Inflammatory Bowel Diseases	Phase 4	Not yet recruiting	August 2020	United States, Massachusetts ... 展开 >> Boston Medical Center Boston, Massachusetts, United States, 02118 收起 <<
NCT01204112	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 收起 <<
NCT03703817	-		Recruiting	November 30, 2018	Korea, Republic of ... 展开 >> Chonbuk National University Hospital Recruiting Jeonju, Jeollabuk-do, Korea, Republic of, 561-712 Wonkwang University Hospital / Division of Rheumatology Recruiting Iksan, Jeonlabuk-do, Korea, Republic of, 570711 Ajou University Hospital, Department of Rheumatology Recruiting Suwon-si, Kyeongki-do, Korea, Republic of, 443-721 Eulji University Hospital Recruiting Daejeon, Republic OF Korea, Korea, Republic of, 35233 Asan Medical Center Recruiting Songpa-gu, Seoul, Korea, Republic of, 138-736 Hallym University Sacred Heart Hospital/Rheumatology, Internal Medicine Recruiting Anyang, Korea, Republic of, 431-070 Inje University Busan Paik Hospital, Department of Internal Medicine Recruiting Busan, Korea, Republic of, 614-735 Kosin University Gospel Hospital Recruiting Busan, Korea, Republic of, 6 Keimyung University Dongsan Medical Center Recruiting Daegu, Korea, Republic of, 700-712 Daegu Catholic University Medical Center, Department of Rheumatology Recruiting Daegu, Korea, Republic of, 705-718 Gacheon Medical School Gil Medical Center, Rheumatology, Internal Medicine Recruiting Incheon, Korea, Republic of, 405-760 Pusan National University Hospital Recruiting Pusan, Korea, Republic of, 602-739 Dong-A University Hospital Recruiting Pusan, Korea, Republic of Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 110-744 Yonsei University Severance Hospital Recruiting Seoul, Korea, Republic of, 120-752 Kyung Hee University Hospital Recruiting Seoul, Korea, Republic of, 130-702 Hanyang University Hospital, Department of Rheumatology Recruiting Seoul, Korea, Republic of, 133-792 Catholic University of Korea, Kangnam St. Mary's Hospital Recruiting Seoul, Korea, Republic of, 137-701 Konkuk University Hospital, Department of Rheumatology Recruiting Seoul, Korea, Republic of, 143-914 Chung-Ang University Hospital Recruiting Seoul, Korea, Republic of, 156-755 Ewha Womans University Mokdong Hospital Recruiting Seoul, Korea, Republic of, 158-056 收起 <<
NCT02092467	Arthritis, Rheumatoid	Phase 4	Recruiting	March 3, 2020	-
NCT02197455	-		Completed	-	-
NCT02197455	Alopecia Areata (AA) ... 展开 >> Alopecia Totalis (AT) Alopecia Universalis (AU) 收起 <<	Phase 2	Completed	-	United States, Connecticut ... 展开 >> Yale University New Haven, Connecticut, United States 收起 <<
NCT01882439	Psoriatic Arthritis	Phase 3	Completed	-	-
NCT01831466	-		Completed	-	-
NCT01262118	-		Completed	-	-
NCT01184092	Rheumatoid Arthritis	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT01184001	Rheumatoid Arthritis	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT03681275	Diaphragm Injury	Phase 1	Not yet recruiting	December 1, 2021	United States, California ... 展开 >> Stanford University Medical Center Not yet recruiting Stanford, California, United States, 94305 Contact: Study team 650-721-2086 donnam@stanford.edu 收起 <<
NCT01226680	Keratoconjunctivitis Sicca	Phase 2	Withdrawn	October 19, 2012	-
NCT02001181	-		Completed	-	-
NCT02001181	Dermatitis, Atopic	Phase 2	Completed	-	Canada, Ontario ... 展开 >> SKiN Centre for Dermatology Peterborough, Ontario, Canada, K9J 1Z2 The Centre for Dermatology Richmond Hill, Ontario, Canada, L4B 1A5 K. Papp Clinical Research Waterloo, Ontario, Canada, N2J 1C4 Canada, Quebec Innovaderm Research Inc. Montreal, Quebec, Canada, H2K 4L5 Canada Centre de Recherche Dermatologique du Quebec metropolitain Quebec, Canada, G1V 4X7 收起 <<
NCT01262118	Rheumatoid Arthritis	Phase 1	Completed	-	United States, Alabama ... 展开 >> Pfizer Investigational Site Anniston, Alabama, United States, 36201 Pfizer Investigational Site Anniston, Alabama, United States, 36207 United States, Arkansas Pfizer Investigational Site Little Rock, Arkansas, United States, 72201 United States, California Pfizer Investigational Site Los Angeles, California, United States, 90095 United States, Florida Pfizer Investigational Site Daytona Beach, Florida, United States, 32114 Pfizer Investigational Site Ormond Beach, Florida, United States, 32174 Pfizer Investigational Site South Miami, Florida, United States, 33143 United States, Michigan Pfizer Investigational Site Bingham Farms, Michigan, United States, 48025 United States, Texas Pfizer Investigational Site Dallas, Texas, United States, 75231 Hungary Pfizer Investigational Site Balatonfured, Hungary, 8230 Pfizer Investigational Site Budapest, Hungary, 1032 收起 <<
NCT01932372	-		Active, not recruiting	January 26, 2021	-
NCT01882439	-		Completed	-	-
NCT02187055	Rhematoid Arthritis	Phase 4	Completed	-	-
NCT01786668	Ankylosing Spondylitis	Phase 2	Completed	-	-
NCT01164579	Rheumatoid Arthritis	Phase 2	Completed	-	-
NCT03598959	Extranodal NK/T-cell Lymphoma	Phase 2	Not yet recruiting	December 31, 2021	China, Sichuan ... 展开 >> West China Hospital of Sichuan University Chengdu, Sichuan, China, 610044 收起 <<
NCT01976364	Arthritis, Psoriatic	Phase 3	Active, not recruiting	July 11, 2019	-
NCT01599377	Healthy	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT01164579	-		Completed	-	-
NCT01786668	-		Completed	-	-
NCT02147587	Rheumatoid Arthritis	Phase 2	Completed	-	-
NCT01499004	Healthy	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT01731327	Healthy	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT02147587	-		Completed	-	-
NCT03502616	Ankylosing Spondylitis	Phase 3	Recruiting	August 2, 2020	-
NCT03288324	Cutaneous Lupus ... 展开 >> Systemic Lupus Erythematosus 收起 <<	Phase 1 Phase 2	Recruiting	August 2020	United States, Ohio ... 展开 >> Cincinnati Childrens Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Angela SR CRC 513-803-2118 angela.merritt@cchmc.org 收起 <<
NCT02187055	-		Completed	-	-
NCT01500551	Juvenile Idiopathic Arthritis	Phase 3	Recruiting	March 31, 2021	-
NCT02831855	Rheumatoid Arthritis	Phase 4	Recruiting	December 17, 2018	-
NCT03000439	Arthritis Juvenile Idiopathic	Phase 3	Recruiting	July 18, 2023	-
NCT02535689	Systemic Lupus Erythematosus	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT03486457	Psoriatic Arthritis	Phase 3	Recruiting	November 26, 2020	China, Anhui ... 展开 >> The First Affiliated Hospital of Bengbu Medical College Not yet recruiting Bengbu, Anhui, China, 233000 China, Hubei Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Not yet recruiting Wuhan, Hubei, China, 430022 China, Hunan The Second Xiangya Hospital of Central South University Not yet recruiting Changsha, Hunan, China, 410011 Zhuzhou Central Hospital Not yet recruiting Zhuzhou, Hunan, China, 412007 China, Inner Mongolia The First Affiliated Hospital of Baotou Medical College Not yet recruiting Baotou, Inner Mongolia, China, 014010 China, Jiangxi Pingxiang People's Hospital Recruiting Pingxiang, Jiangxi, China, 337055 China, Tianjin Tianjin Medical University General Hospital, Rheumatology and Immunology Department Recruiting Tianjin, Tianjin, China, 300052 China, Yunnan First Affiliated Hospital of Kunming Medical University Not yet recruiting Kunming, Yunnan, China, 650032 China, Zhejiang The First Affiliated Hosptial of Wenzhou University Recruiting Wenzhou, Zhejiang, China, 325000 China Rheumatology and Immunology Department, Xuanwu Hospital Capital Medical University Not yet recruiting Beijing, China, 100053 收起 <<
NCT03738956	Axial Spondyloarthritis	Phase 2 Phase 3	Recruiting	December 31, 2018	Bangladesh ... 展开 >> Bangabandhu sheikh mujib medical university Recruiting Dhaka, Bangladesh, 1205 Contact: Asadul Islam, MBBS +8801721446630 asad.kmc13@gmail.com Contact: Prayush Sharma, MBBS +8801535157897 drprayush@gmail.com Principal Investigator: Asadul Islam, MBBS 收起 <<
NCT02321930	Rheumatoid Arthritis	Phase 4	Completed	-	United States, California ... 展开 >> UCLA David Geffen School of Medicine, Division of Rheumatology Los Angeles, California, United States, 90095 收起 <<
NCT02084875	Healthy	Phase 1	Completed	-	United States, California ... 展开 >> Glendale Adventist Medical Center Glendale, California, United States, 91206 收起 <<
NCT03772145	-		Recruiting	December 31, 2021	United States, North Carolina ... 展开 >> Division of Gastroenterology and Hepatology Recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Emily English 919-843-8105 ext 8105‬‬‬ emily_english@med.unc.edu 收起 <<
NCT02487433	Healthy	Phase 1	Completed	-	Belgium ... 展开 >> Pfizer Clinical Research Unit Brussels, Belgium, B-1070 收起 <<
NCT03387423	-		Recruiting	February 11, 2023	-
NCT02812342	Alopecia Areata ... 展开 >> Alopecia Totalis Alopecia Universalis 收起 <<	Phase 2	Active, not recruiting	December 2018	United States, Connecticut ... 展开 >> Yale-New Haven Hospital New Haven, Connecticut, United States, 06510 收起 <<
NCT02812342	-		Active, not recruiting	-	-
NCT02566967	Rheumatoid Arthritis	Phase 3	Active, not recruiting	December 2017	United States, Florida ... 展开 >> AARDS Research, Inc. Aventura, Florida, United States, 33180 收起 <<
NCT03580343	Uveitis Scler... 展开 >>itis 收起 <<	Phase 2	Not yet recruiting	September 2020	-
NCT03504072	Spondyloarthritis	Phase 4	Recruiting	December 31, 2019	Bangladesh ... 展开 >> Bangabandhu Sheikh Mujib Medical University Recruiting Dhaka, Bangladesh Contact: Nazrul Islam, FCPS, MD 收起 <<
NCT01202240	Healthy	Phase 1	Completed	-	Belgium ... 展开 >> Pfizer Investigational Site Bruxelles, Belgium, B-1070 收起 <<
NCT02281552	Rheumatoid Arthritis	Phase 3	Completed	-	Japan ... 展开 >> Japanese Red Cross Nagoya Daiichi Hospital Nagoya, Aichi, Japan, 453-8511 National Hospital Organization Nagoya Medical Center Nagoya, Aichi, Japan, 460-0001 National Hospital Organization Toyohashi Medical Center Toyohashi, Aichi, Japan, 440-8510 Yamada Rheumatology Clinic Matsuyama, Ehime, Japan, 790-0905 St. Mary's Hospital Kurume, Fukuoka, Japan, 830-8543 Gunma Rheumatism Clinic Takasaki-shi, Gunma, Japan, 370-0004 Inoue Hospital Tohrimachi, Takasaki, Gunma, Japan, 370-0053 Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima-city, Hiroshima, Japan, 730-8619 National Hospital Organization Asahikawa Medical Center Asahikawa, Hokkaido, Japan, 070-8644 Katayama Orthopaedic Rheumatology Clinic Asahikawa, Hokkaido, Japan, 078-8243 Yoshida orthopaedics and rheumatologyclinic Morioka, Iwate, Japan, 020-0015 Komagamine Rheumatoid Orthopaedic Clinic Morioka, Iwate, Japan, 020-0034 National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan, 252-0392 National Hospital Organization Yokohama Medical Center Yokohama, Kanagawa, Japan, 245-8575 Osaki Citizen Hospital Oosaki, Miyagi, Japan, 989-6183 Tohoku University Hospital/ Department of Hematology and Rheumatology Sendai, Miyagi, Japan, 9808574 Nagano Red Cross Hospital Nagano-shi, Nagano, Japan, 380-8582 Sasebo Chuo Hospital Sasebo, Nagasaki, Japan, 857-1195 National Hospital Organization Ureshino Medical Center Ureshino-shi, Saga, Japan, 843-0393 Soshigayaokura clinic Setagaya-ku, Tokyo, Japan, 157-0073 Showa University Hospital Shinagawa-ku, Tokyo, Japan, 142-8666 Honjo Rheumatism Clinic Takaoka-shi, Toyama, Japan, 933-0874 Miyasato Clinic Shunan, Yamaguchi, Japan, 745-0824 National Hospital Organization Chiba-East Hospital Chiba, Japan, 260-8712 Sugimoto rheumatology and internal medicine clinic Fukui, Japan, 910-0068 National Hospital Organization Kyushu Medical Center Fukuoka, Japan, 810-8563 SHONO Rheumatism Clinic Fukuoka, Japan, 814-0002 Sagawa Akira Rheumatology Clinic Hokkaido, Japan, 060-0001 Matsubara Mayflower Hospital Hyogo, Japan, 673-1462 Yokohama Minami Kyosai Hospital Kanagawa, Japan, 236-0037 Kumamoto Orthopaedic Hospital Kumamoto, Japan, 862-0976 Japanese Red Cross Kyoto Daiichi Hospital Kyoto, Japan, 605-0981 Oribe Clinic of Rheumatology and Internal Medicine Oita, Japan, 870-0823 Otsuka Clinic of Rheumatism and Medicine Oita, Japan, 870-1155 Rabbit Clinic Saitama, Japan, 336-0911 Hirose Clinic Saitama, Japan, 359-1111 收起 <<
NCT02281552	-		Completed	-	-
NCT03011281	-		Recruiting	December 2021	Korea, Republic of ... 展开 >> Hanyang University Recruiting Seoul, Korea, Republic of, 04763 Contact: Yoon-kyoung Sung, MD, PhD, MPH 82-2-2290-9250 sungyk@hanyang.ac.kr 收起 <<
NCT02592434	Juvenile Idiopathic Arthritis	Phase 3	Recruiting	May 21, 2019	-
NCT03274076	Systemic Sclerosis ... 展开 >> Scleroderma 收起 <<	Phase 1 Phase 2	Active, not recruiting	December 2019	United States, Michigan ... 展开 >> University of Michigan Ann Arbor, Michigan, United States, 48104 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15261 收起 <<
NCT02312882	Alopecia Areata ... 展开 >> Alopecia Totalis Alopecia Universalis 收起 <<	Not Applicable	Completed	-	United States, California ... 展开 >> Stanford University Stanford, California, United States, 94305 收起 <<
NCT02299297	Alopecia Areata	Phase 2	Active, not recruiting	November 2017	United States, New York ... 展开 >> Columbia University Medical Center New York, New York, United States, 10032 收起 <<
NCT03159936	Discoid Lupus Erythematosus ... 展开 >> Systemic Lupus Erythematosus 收起 <<	Early Phase 1	Recruiting	April 2019	United States, Massachusetts ... 展开 >> Tufts Medical Center Recruiting Boston, Massachusetts, United States, 02111 Contact: Nicole Dumont 617-636-7462 ndonovan1@tuftsmedicalcenter.org 收起 <<
NCT03736161	Psoriatic Arthritis	Phase 3	Recruiting	February 28, 2019	Bangladesh ... 展开 >> Bangabandhu Sheikh Mujib Medical University Recruiting Dhaka, Bangladesh, 1205 Contact: Prayush Sharma, MBBS +8801535157897 drprayush@gmail.com 收起 <<
NCT02312882	-		Completed	-	-
NCT03002649	Dermatomyositis	Phase 1	Recruiting	June 2019	United States, Maryland ... 展开 >> Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21224 Contact: Julie Paik, MD 410-550-1741 Principal Investigator: Julie Paik, MD 收起 <<

Ba/F3 cells		Function assay	60 mins	Inhibition of TEL-fused JAK1 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay, IC50=26 nM.	22087750
Ba/F3 cells		Function assay	60 mins	Inhibition of TEL-fused JAK3 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay, IC50=54 nM.	22087750
human CD4+ T cells	5 to 500 nM	Function assay	1 h	Inhibition of IL2-induced Stat5 phosphorylation in human CD4+ T cells at 5 to 500 nM after 1 hr by Western blot	19053756
human DND/L12 cells		Function assay	30 mins	Inhibition of JAK3 in human DND/L12 cells after 30 mins by luciferase assay in presence of human serum albumin.	14593182
human Hs578T cells	3 μM	Function assay	16 h	Induction of PTPN6 in human Hs578T cells assessed as inhibition of STAT3 phosphorylation at 3 uM after 16 hrs by Western blotting analysis in presence of pervanadate	24978112
human Huh7 cells	10 μM	Function assay	30 mins	Inhibition of Tyk2 in human Huh7 cells assessed as reduction of IFNalpha5-induced STAT3 phosphorylation at 10 uM pre-incubated for 30 mins before IFNalpha5 stimulation for 30 mins mins by immunoblotting	26231159
human Huh7 cells	10 μM	Function assay	30 mins	Inhibition of Tyk2 in human Huh7 cells assessed as reduction of basal level STAT3 phosphorylation at 10 uM after 30 mins by immunoblotting	26231159
human HUO3 cells		Function assay	4 days	Inhibition of human GM-CSF-induced proliferation in human HUO3 cells assessed as [3H]thymidine incorporation after 4 days by scintillation counting, IC50=0.324 μM.	14593182
human Jurkat cells		Function assay	24 h	Inhibition of anti-CD3/anti-CD28-induced IL2 production in human Jurkat cells after 24 hrs by scintillation counting, IC50=7.84 μM.	14593182
human MO7 cells		Function assay		Inhibition of Jak3-mediated IL15-induced Stat5 phosphorylation in human MO7 cells by cell-based assay, IC50=24 nM.	21155605
human monocytes		Function assay		Inhibition of JAK2 in human monocytes expressing CD14 assessed as inhibition of GM-CSF-stimulated STAT5a phosphorylation, IC50=0.184 μM.	23540648
human NK92 cells		Function assay	20 mins	Inhibition of TYK2 in human NK92 cells assessed as inhibition of IL12-induced STAT4 phosphorylation incubated for 20 mins followed by IL12 challenge for 45 mins, EC50=0.71 μM.	23659214
human OCL-AML5 cells	1 μM	Function assay	3 h	Inhibition of JAK2 in human OCL-AML5 cells assessed as inhibition of GM-CSF induced STAT5 phosphorylation at 1 uM preincubated for 3 hrs followed by GM-CSF induction measured after 30 mins by immunoblotting	26258521
human PBMC		Function assay	30 mins	Inhibition of JAK1/JAK3 in human PBMC assessed as inhibition of IL2-stimulated STATs phosphorylation preincubated for 30 mins prior to IL2 challenge measured after 15 mins by intracellular phosflow staining, IC50=33 nM.	22087750
human SUM149PT cells	3 μM	Function assay	16 h	Induction of PTPN6 in human SUM149PT cells assessed as inhibition of STAT3 phosphorylation at 3 uM after 16 hrs by Western blotting analysis in presence of pervanadate	24978112
human T cells		Function assay		Inhibition of JAK3/1 in human T cells expressing CD3 assessed as inhibition of IL2-stimulated STAT5a phosphorylation， IC50=28 nM.	23540648
human TALL-1 cells		Function assay		Inhibition of JAK3 in human TALL-1 cells assessed as inhibition of IL-2 induced STAT5 phosphorylation at 1 uM preincubated for 3 hrs followed by IL-2 induction measured after 30 mins by immunoblotting	26258521
human TF1 cells		Function assay	20 mins	Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins followed by IL6 challenge for 30 mins in presence of whole blood， EC50=43 nM.	23659214
human UT7 cells		Function assay		Inhibition of JAK2 in human UT7 cells assessed as suppression of EPO-stimulated STAT5 phosphorylation by AlphaScreen assay	26372653
human YT cells	30 ng/ml	Function assay		Inhibition of IL2-induced JAK3 phosphorylation in human YT cells at 30 ng/ml by immunoblotting analysis	14593182
monkey T cells		Function assay		Inhibition of allogenic cells-stimulated proliferation in monkey T cells by mixed lymphocyte reaction method, IC50=57 nM.	14593182
mouse BAF3 cells		Proliferation assay	72 h	Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK3 kinase after 72 hrs by alamar blue assay, IC50=0.57 μM.	19762238
mouse CTLL cells		Function assay		Inhibition of Jak3-mediated IL2-induced Stat5 phosphorylation in mouse CTLL cells by cell-based assay, IC50=48 nM.	21155605
SF21 cells		Function assay	10 mins	Inhibition of JAK2 (unknown origin) expressed in SF21 cells using Biotin-KAIETDKEYYTVKD as substrate and [33Pgamma]ATP incubated for 10 mins prior to substrate addition measured after 30 mins by Topcount analysis, IC50=4 nM.	23541670
Sf9 cells		Function assay	30 mins	Inhibition of human GST-fused JAK3 catalytic domain expressed in baculovirus-infected Sf9 cells using polyglutamic acid-tyrosine as substrate after 30 mins by ELISA, Ki=0.4 nM.	23668484
Sf9 cells		Function assay	90 mins	Inhibition of human recombinant N-terminal GST-tagged JAK3 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay, IC50=0.6 nM.	22087750
TF1 cells		Function assay		Inhibition of IL3-induced proliferation of TF1 cells， IC50=0.8 μM.	16934457

枸橼酸托法替尼 /Tofacitinib citrate 99%

Tofacitinib citrate 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Tofacitinib citrate 质控信息

Tofacitinib citrate 生物活性

Tofacitinib citrate 细胞研究

Tofacitinib citrate 动物研究

Tofacitinib citrate 临床研究

Tofacitinib citrate 参考文献

Tofacitinib citrate 实验方案

Tofacitinib citrate 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

枸橼酸托法替尼 /Tofacitinib citrate 99%

Tofacitinib citrate 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Tofacitinib citrate 质控信息

Tofacitinib citrate 生物活性

Tofacitinib citrate 细胞研究

Tofacitinib citrate 动物研究

Tofacitinib citrate 临床研究

Tofacitinib citrate 参考文献

Tofacitinib citrate 实验方案

Tofacitinib citrate 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Tofacitinib citrate 纯度/质量文件产品仅供科研